In this retrospective study, we analyzed 177 patients with high-grade serous tubo-ovarian and peritoneal cancers who received PARP inhibitors (olaparib, niraparib, or rucaparib) as maintenance therapy between 2017 and 2025 at a single large cancer centre. This evidence concerns the gene PARP1 and cancer.